A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Babies

• Status: Completed
• Trial end date: 2001-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if giving the anti-HIV drug nevirapine (NVP) to HIV-positive pregnant women and their babies can help reduce the chance that a mother will give HIV to her baby during delivery.

Previous studies suggest that NVP is a promising medication for blocking HIV transmission from HIV-positive mothers to their babies.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Treatments: Nevirapine

Criteria

Inclusion Criteria

You may be eligible for this study if you:

• Are an HIV-positive pregnant woman.

• Have been pregnant for at least 28 weeks.

• Are at least 13 years of age (consent of parent or guardian is required if under 18).

Exclusion Criteria

You will not be eligible for this study if:

• Your baby will not live.

• You intend to breast-feed.

• You are allergic to benzodiazepines (a tranquilizer).

• You have a liver disorder.

• You have received non-nucleoside reverse transcriptase inhibitors (a class of anti-HIV drugs).